Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.191 |
---|---|
High | 0.191 |
Low | 0.191 |
Bid | 0.204 |
Offer | 0.242 |
Previous close | 0.2540 |
Average volume | 2.86k |
---|---|
Shares outstanding | 57.14m |
Free float | 51.68m |
P/E (TTM) | -- |
Market cap | 15.27m USD |
EPS (TTM) | -0.5703 USD |
Data delayed at least 15 minutes, as of Sep 23 2024 07:08 BST.
More ▼
Announcements
- AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
- AIM ImmunoTech Announces that Analysis of AMP-518 Complete Clinical Patient Data Underscores Ampligen’s Potential to Improve the Post-COVID Condition of Fatigue
- AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
- AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and Webcast
- AIM ImmunoTech Announces Release of the Next CEO Corner Segment
- AIM Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination Therapy
- AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference
- AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series
- AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering
More ▼